MS27 PROTHROMBOTIC MARKERS IN DYSLIPIDEMIC PATIENTS

Abstract

Patients with type 1 diabetes often develop diabetic ketoacidosis (DKA). Reportedly, DKA in type 2 diabetes has higher mortality despite its limited occurrence. The exact clinical characteristics and therapeutic modalities yielding successful outcomes in DKA type 2 diabetes remain unknown.This retrospective study compared the clinical features and detailed treatment of consecutive type 1 and type 2 diabetes patients hospitalized with DKA between January 2001 and December 2014.We report on 127 patients with type 1 and 74 patients with type 2 diabetes whose DKA was successfully treated. The most frequent precipitating cause for DKA was infectious disease for patients with type 1 diabetes and consumption of sugar-containing beverages for those with type 2 diabetes. Type 2 diabetes patients showed higher mean plasma glucose levels than those with type 1 diabetes (48.4 ± 21.6, vs. 37.1 ± 16.4 mmol/l, P < 0.01) and higher serum creatinine, blood urea nitrogen, and hemoglobin levels, which normalized after DKA resolution. Compared with type 1 diabetes patients, those with type 2 diabetes required distinctly higher daily total insulin dosage (35.9 ± 37.0 U, vs. 20.2 ± 23.3 U, P < 0.01), larger replacement fluid volumes (4.17 ± 2.69 L, vs. 2.29 ± 1.57 L, P < 0.01) and greater potassium supplementation (23.9 ± 36.5 mEq, vs. 11.2 ± 17.9 mEq, P < 0.01) to resolve DKA and reduce plasma glucose level to ≤ 16.7 mmol/l.DKA patients with type 2 diabetes required management with a modified treatment protocol to resolve their profound hyperglycemia and dehydration compared with those with type 1 diabetes.